COYA
Coya Therapeutics, Inc.
Price Chart
Latest Quote
$4.90
-0.13 (-2.59%)
Current Price
| Previous Close | $5.03 |
| Open | $5.09 |
| Day High | $5.13 |
| Day Low | $4.88 |
| Volume | 100,853 |
Stock Information
| Shares Outstanding | 23.46M |
| Cash Equivalents | $50.72M |
| Revenue | $7.94M |
| Net Income | $-21.13M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $115.41M |
| EPS (TTM) | $-1.15 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $64.68M |
| Sales | $7.94M |
| Income | $-21.13M |
| Book/sh | $2.09 |
| Cash/sh | $2.16 |
| Employees | 8 |
Financial Ratios
| Quick Ratio | 14.30 |
| Current Ratio | 15.02 |
Returns & Margins
| ROA | -27.57% |
| ROE | -51.31% |
| Gross Margin | -96.71% |
| Operating Margin | -3038.15% |
| Profit Margin | -266.11% |
Ownership
| Insider Ownership | 14.69% |
| Institutional Ownership | 35.37% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.69 |
| P/S | 14.54 |
| P/B | 2.36 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $15.21 |
Technical Indicators
| SMA20 | $4.74 |
| SMA50 | $4.57 |
| SMA200 | $5.20 |
| RSI | 52.29 |
| ATR | 0.3680 |
| Shares Float | 17.54M |
| Short Float | 3.96% |
| Short Ratio | 5.95 |
| Volatility | 0.62 |
| Rel Volume | 1.39 |
Performance History
| Week | +6.03% |
| Month | +7.66% |
| Quarter | +15.22% |
| 6 Months | -15.61% |
| YTD | -12.92% |
| Year | -7.52% |
| 3 Years | -5.75% |
| 10 Years | +7.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.92 | 215,700 |
| 2026-06-17 | $5.03 | 322,200 |
| 2026-06-16 | $4.82 | 154,000 |
| 2026-06-15 | $4.89 | 186,700 |
| 2026-06-12 | $4.74 | 115,000 |
| 2026-06-11 | $4.64 | 175,100 |
| 2026-06-10 | $4.41 | 116,500 |
| 2026-06-09 | $4.48 | 93,100 |
| 2026-06-08 | $4.55 | 83,700 |
| 2026-06-05 | $4.42 | 234,200 |
| 2026-06-04 | $4.87 | 156,100 |
| 2026-06-03 | $4.64 | 118,000 |
| 2026-06-02 | $4.73 | 201,400 |
| 2026-06-01 | $4.91 | 401,200 |
| 2026-05-29 | $4.82 | 118,700 |
| 2026-05-28 | $4.83 | 86,600 |
| 2026-05-27 | $4.77 | 57,700 |
| 2026-05-26 | $4.71 | 93,100 |
| 2026-05-22 | $4.81 | 76,000 |
| 2026-05-21 | $4.84 | 99,700 |
| 2026-05-20 | $4.62 | 66,000 |
| 2026-05-19 | $4.57 | 86,000 |
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
đ° Latest News
Coya Therapeutics secures FDA fast track status for COYA 302
Pharmaceutical Technology âĸ 2026-05-14T11:15:00Z
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs
Exec Edge âĸ 2026-05-12T12:35:06Z
NanoViricides to Participate at D. Boral Capital Global Conference in NYC
Exec Edge âĸ 2026-05-07T12:35:07Z
NanoViricidesâ Measles Treatment Granted Orphan Drug Designation by FDA
Exec Edge âĸ 2026-05-06T12:35:33Z
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2026-02-25T17:00:04Z
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar
MarketBeat âĸ 2026-02-17T21:35:52Z
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement
TipRanks âĸ 2026-01-31T13:15:29Z
ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman
Exec Edge âĸ 2025-12-02T21:46:40Z
Hereâs Greenlight Capitalâs Update on Coya Therapeutics (COYA)
Insider Monkey âĸ 2025-10-28T11:41:37Z
Investors Digest September Inflation Report, Lifting US Equity Futures Pre-Bell
MT Newswires âĸ 2025-10-24T13:20:54Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $7,945,753 | $3,554,061 | $6,002,206 | $0 |
| Operating Revenue | $7,945,753 | $3,554,061 | $6,002,206 | $0 |
| Expenses | ||||
| Total Expenses | $30,500,978 | $20,803,772 | $13,905,555 | $9,811,939 |
| Other Income Expense | $1,332,207 | $1,648,637 | $639,365 | $-2,432,837 |
| Other Non Operating Income Expenses | $1,332,207 | $1,648,637 | $639,365 | $63,673 |
| Operating Expense | $30,500,978 | $20,803,772 | $13,905,555 | $9,811,939 |
| General And Administrative Expense | $11,449,466 | $8,885,757 | $7,833,481 | $4,847,080 |
| Interest Expense | - | - | - | - |
| Net Non Operating Interest Income Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-21,226,107 | $-14,880,787 | $-7,987,836 | $-12,244,776 |
| Normalized Income | $-21,226,107 | $-14,880,787 | $-7,987,836 | $-9,748,266 |
| Net Income From Continuing And Discontinued Operation | $-21,226,107 | $-14,880,787 | $-7,987,836 | $-12,244,776 |
| Total Operating Income As Reported | $-22,555,225 | $-17,249,711 | $-7,903,349 | $-9,811,939 |
| Net Income Common Stockholders | $-21,226,107 | $-14,880,787 | $-7,987,836 | $-12,244,776 |
| Net Income | $-21,226,107 | $-14,880,787 | $-7,987,836 | $-12,244,776 |
| Net Income Including Noncontrolling Interests | $-21,226,107 | $-14,880,787 | $-7,987,836 | $-12,244,776 |
| Net Income Continuous Operations | $-21,226,107 | $-14,880,787 | $-7,987,836 | $-12,244,776 |
| Pretax Income | $-21,223,018 | $-15,601,074 | $-7,263,984 | $-12,244,776 |
| Operating Income | $-22,555,225 | $-17,249,711 | $-7,903,349 | $-9,811,939 |
| Depreciation Amortization Depletion Income Statement | $27,361 | $27,361 | $27,361 | $27,361 |
| Depreciation And Amortization In Income Statement | $27,361 | $27,361 | $27,361 | $27,361 |
| Depreciation Income Statement | $27,361 | $27,361 | $27,361 | $27,361 |
| Special Income Charges | - | - | $-543,186 | $-525,000 |
| Net Interest Income | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-1.27 | $-0.98 | $-0.79 | $-4.73 |
| Basic EPS | $-1.27 | $-0.98 | $-0.79 | $-4.73 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-22,527,864 | $-17,222,350 | $-7,875,988 | $-7,288,068 |
| Reconciled Depreciation | $27,361 | $27,361 | $27,361 | $27,361 |
| EBITDA (Bullshit earnings) | $-22,527,864 | $-17,222,350 | $-7,875,988 | $-9,784,578 |
| EBIT | $-22,555,225 | $-17,249,711 | $-7,903,349 | $-9,811,939 |
| Diluted Average Shares | $16,730,274 | $15,238,919 | $10,163,850 | $2,590,173 |
| Basic Average Shares | $16,730,274 | $15,238,919 | $10,163,850 | $2,590,173 |
| Diluted NI Availto Com Stockholders | $-21,226,107 | $-14,880,787 | $-7,987,836 | $-12,244,776 |
| Tax Provision | $3,089 | $-720,287 | $723,852 | $0 |
| Research And Development | $19,024,151 | $11,890,654 | $6,044,713 | $4,937,498 |
| Selling General And Administration | $11,449,466 | $8,885,757 | $7,833,481 | $4,847,080 |
| Other Gand A | $11,449,466 | $8,885,757 | $7,833,481 | $4,847,080 |
| Total Unusual Items | - | - | $-543,186 | $-2,496,510 |
| Total Unusual Items Excluding Goodwill | - | - | $-543,186 | $-2,496,510 |
| Other Special Charges | - | - | $543,186 | $525,000 |
| Gain On Sale Of Security | - | - | - | $-2,496,510 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $43,028,230 | $39,577,095 | $35,635,609 | $-8,393,545 |
| Total Assets | $49,950,245 | $44,347,016 | $41,262,274 | $8,395,566 |
| Total Non Current Assets | $11,227 | $38,588 | $65,949 | $1,210,600 |
| Current Assets | $49,939,018 | $44,308,428 | $41,196,325 | $7,184,966 |
| Prepaid Assets | $3,116,232 | $5,238,085 | $1,069,557 | $1,251,264 |
| Receivables | $0 | $730,581 | $7,500,000 | $0 |
| Taxes Receivable | $0 | $730,581 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $46,822,786 | $38,339,762 | $32,626,768 | $5,933,702 |
| Cash And Cash Equivalents | $46,822,786 | $38,339,762 | $32,626,768 | $5,933,702 |
| Non Current Deferred Assets | - | - | $0 | $1,117,290 |
| Other Receivables | - | - | $7,500,000 | - |
| Debt | ||||
| Net Debt | - | - | - | $7,031,778 |
| Total Debt | - | - | - | $12,965,480 |
| Long Term Debt And Capital Lease Obligation | - | - | - | $12,965,480 |
| Long Term Debt | - | - | - | $12,965,480 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,922,015 | $4,769,921 | $5,626,665 | $16,789,111 |
| Total Non Current Liabilities Net Minority Interest | $1,050,124 | $945,447 | $574,685 | $12,965,480 |
| Non Current Deferred Liabilities | $1,050,124 | $945,447 | $574,685 | $0 |
| Current Liabilities | $5,871,891 | $3,824,474 | $5,051,980 | $3,823,631 |
| Current Deferred Liabilities | $1,197,856 | $848,286 | $923,109 | $0 |
| Payables And Accrued Expenses | $4,674,035 | $2,976,188 | $4,128,871 | $3,823,631 |
| Payables | $1,061,122 | $1,588,128 | $1,879,508 | $1,815,270 |
| Accounts Payable | $1,061,122 | $1,588,128 | $1,155,656 | $1,815,270 |
| Total Tax Payable | - | $0 | $723,852 | $0 |
| Income Tax Payable | - | $0 | $723,852 | $0 |
| Equity | ||||
| Common Stock Equity | $43,028,230 | $39,577,095 | $35,635,609 | $-17,187,182 |
| Total Equity Gross Minority Interest | $43,028,230 | $39,577,095 | $35,635,609 | $-8,393,545 |
| Stockholders Equity | $43,028,230 | $39,577,095 | $35,635,609 | $-8,393,545 |
| Retained Earnings | $-61,963,277 | $-40,737,170 | $-25,856,383 | $-17,868,547 |
| Other Equity Interest | - | - | $-11,250 | - |
| Preferred Stock Equity | - | - | - | $8,793,637 |
| Other | ||||
| Ordinary Shares Number | $20,934,456 | $16,707,441 | $14,405,325 | $9,679,408 |
| Share Issued | $20,934,456 | $16,707,441 | $14,405,325 | $9,679,408 |
| Tangible Book Value | $43,028,230 | $39,577,095 | $35,635,609 | $-17,187,182 |
| Invested Capital | $43,028,230 | $39,577,095 | $35,635,609 | $-4,221,702 |
| Working Capital | $44,067,127 | $40,483,954 | $36,144,345 | $3,361,335 |
| Total Capitalization | $43,028,230 | $39,577,095 | $35,635,609 | $4,571,935 |
| Additional Paid In Capital | $104,989,413 | $80,312,594 | $61,501,801 | $681,106 |
| Capital Stock | $2,094 | $1,671 | $1,441 | $8,793,896 |
| Common Stock | $2,094 | $1,671 | $1,441 | $259 |
| Preferred Stock | $0 | $0 | $0 | $8,793,637 |
| Non Current Deferred Revenue | $1,050,124 | $945,447 | $574,685 | $0 |
| Current Deferred Revenue | $1,197,856 | $848,286 | $923,109 | $0 |
| Current Accrued Expenses | $3,612,913 | $1,388,060 | $2,249,363 | $2,008,361 |
| Net PPE | $11,227 | $38,588 | $65,949 | $93,310 |
| Accumulated Depreciation | - | $-98,216 | $-70,855 | $-43,494 |
| Gross PPE | - | $136,804 | $136,804 | $136,804 |
| Other Properties | - | $136,804 | $136,804 | $136,804 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,739,301 | $-10,288,822 | $-11,188,811 | $-7,239,354 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,739,301 | $-10,288,822 | $-11,188,811 | $-7,239,354 |
| Cash Flow From Continuing Operating Activities | $-10,739,301 | $-10,288,822 | $-11,188,811 | $-7,239,354 |
| Investing Activities | ||||
| Investing Cash Flow | $-1,164,602 | $-25,000 | $-543,186 | $-525,000 |
| Cash Flow From Continuing Investing Activities | $-1,164,602 | $-25,000 | $-543,186 | $-525,000 |
| Net Other Investing Changes | $-1,164,602 | $-25,000 | $-543,186 | $-525,000 |
| Capital Expenditure | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $20,348,653 | $14,004,381 | $38,335,116 | $0 |
| Financing Cash Flow | $20,386,927 | $16,026,816 | $38,425,063 | $9,357,878 |
| Cash Flow From Continuing Financing Activities | $20,386,927 | $16,026,816 | $38,425,063 | $9,357,878 |
| Net Common Stock Issuance | $20,348,653 | $14,004,381 | $38,335,116 | $0 |
| Common Stock Issuance | $20,348,653 | $14,004,381 | $38,335,116 | $0 |
| Net Other Financing Charges | - | $-120,668 | - | $-1,111,250 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $46,822,786 | $38,339,762 | $32,626,768 | $5,933,702 |
| Beginning Cash Position | $38,339,762 | $32,626,768 | $5,933,702 | $4,340,178 |
| Changes In Cash | $8,483,024 | $5,712,994 | $26,693,066 | $1,593,524 |
| Proceeds From Stock Option Exercised | $38,274 | $2,143,103 | $89,947 | $158 |
| Change In Working Capital | $3,879,528 | $1,876,065 | $-4,643,770 | $751,838 |
| Change In Other Working Capital | $454,247 | $295,939 | $1,497,794 | - |
| Change In Payables And Accrued Expense | $572,847 | $-1,020,765 | $1,176,729 | $1,671,840 |
| Change In Accrued Expense | $1,099,853 | $-1,498,215 | $877,913 | $826,556 |
| Change In Payable | $-527,006 | $477,450 | $298,816 | $845,284 |
| Change In Account Payable | $-527,006 | $477,450 | $298,816 | $845,284 |
| Change In Prepaid Assets | $2,852,434 | $-4,899,109 | $181,707 | $-920,002 |
| Change In Receivables | $0 | $7,500,000 | $-7,500,000 | $0 |
| Other Non Cash Items | $2,289,602 | $25,000 | $543,186 | $4,018,877 |
| Stock Based Compensation | $4,290,315 | $2,663,539 | $872,248 | $207,346 |
| Depreciation Amortization Depletion | $27,361 | $27,361 | $27,361 | $27,361 |
| Depreciation And Amortization | $27,361 | $27,361 | $27,361 | $27,361 |
| Depreciation | $27,361 | $27,361 | $27,361 | $27,361 |
| Net Income From Continuing Operations | $-21,226,107 | $-14,880,787 | $-7,987,836 | $-12,244,776 |
| Issuance Of Debt | - | - | $0 | $10,468,970 |
| Net Issuance Payments Of Debt | - | - | $0 | $10,468,970 |
| Net Long Term Debt Issuance | - | - | $0 | $10,468,970 |
| Long Term Debt Issuance | - | - | $0 | $10,468,970 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $0 |
Fetched: 2026-06-17